Indian clinical practice consensus guidelines for the management of very advanced disease of squamous cell carcinoma of head and neck

• Published in: Indian journal of cancer Vol. 57; no. 5; pp. 22 - 25
• Main Authors: Prabhash, Kumar, Babu, Govind, Chaturvedi, Pankaj, Kuriakose, Moni, Birur, Praveen, Anand, Anil, Kaushal, Ashish, Mahajan, Abhishek, Syiemlieh, Judita, Singhal, Manish, Gairola, Munish, Ramachandra, Prakash, Goyal, Sumit, John, Subashini, Nayyar, Rohit, Patil, Vijay, Rao, Vishal, Roshan, Vikas, K, Rath
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.02.2020; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd
• Subjects: Cancer; Cancer metastasis; Cancer therapies; Cancer treatment; Carboplatin; Carcinoma; Care and treatment; Cetuximab; Chemotherapy; Diseases; Head & neck cancer; Immunomodulators; Immunotherapy; Metastasis; Monoclonal antibodies; Nivolumab; Oral cancer; Pembrolizumab; Practice guidelines (Medicine); Radiation therapy; Squamous cell carcinoma; Surgery; Targeted cancer therapy; Sri Lanka; India
• ISSN: 0019-509X; 1998-4774
• DOI: 10.4103/0019-509X.278977

Systemic therapy Single-agent systemic therapy including cisplatin/carboplatin/paclitaxel/docetaxel/5-FU/methotrexate/cetuximab/gemcitabine/capecitabine combination CT may be considered. Pembrolizumab is recommended as a single agent in patients with a combined positive score (CPS) ≥20, and in combination with or without platinum plus FU in patients with CPS ≥1 and <20 (EL 1; Grade A)[5],[6] Nivolumab is recommended as single agent if disease has progressed during or within 6 months of platinum-based therapy (EL 1; Grade A)[7]Cisplatin/5-FUCisplatin or carboplatin/docetaxel or paclitaxelCisplatin or carboplatin/docetaxel/cetuximabCisplatin or carboplatin/paclitaxel/cetuximab. The task force members have taken this educational initiative of developing India specific consensus guidelines for management of head and neck cancer under its ambit.